South Korea · Delayed Price · Currency is KRW Plumbline Life Sciences Statistics
Total Valuation
XKON:222670 has a market cap or net worth of KRW 21.92 billion.
| Market Cap | 21.92B |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
XKON:222670 has 3.67 million shares outstanding.
| Current Share Class | 3.67M |
| Shares Outstanding | 3.67M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 22.01 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.42, with a Debt / Equity ratio of 1.10.
| Current Ratio | 0.42 |
| Quick Ratio | 0.37 |
| Debt / Equity | 1.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | -3.25 |
| Interest Coverage | -14.02 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -29.61% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +11.03% in the last 52 weeks. The beta is 0.34, so XKON:222670's price volatility has been lower than the market average.
| Beta (5Y) | 0.34 |
| 52-Week Price Change | +11.03% |
| 50-Day Moving Average | 6,694.80 |
| 200-Day Moving Average | 6,136.73 |
| Relative Strength Index (RSI) | 39.01 |
| Average Volume (20 Days) | 1,120 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -590.62M |
| Pretax Income | -773.99M |
| Net Income | -773.99M |
| EBITDA | -348.84M |
| EBIT | -590.62M |
| Earnings Per Share (EPS) | -771.00 |
Balance Sheet
The company has 435.61 million in cash and 1.10 billion in debt, giving a net cash position of -663.59 million or -181.04 per share.
| Cash & Cash Equivalents | 435.61M |
| Total Debt | 1.10B |
| Net Cash | -663.59M |
| Net Cash Per Share | -181.04 |
| Equity (Book Value) | 996.08M |
| Book Value Per Share | 992.23 |
| Working Capital | -674.57M |
Cash Flow
In the last 12 months, operating cash flow was -336.10 million and capital expenditures -2.50 million, giving a free cash flow of -338.61 million.
| Operating Cash Flow | -336.10M |
| Capital Expenditures | -2.50M |
| Free Cash Flow | -338.61M |
| FCF Per Share | -92.38 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
XKON:222670 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -3.53% |
| FCF Yield | -1.54% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |